dc.contributor.author | Caswell, DR | |
dc.contributor.author | Gui, P | |
dc.contributor.author | Mayekar, MK | |
dc.contributor.author | Law, EK | |
dc.contributor.author | Pich, O | |
dc.contributor.author | Bailey, C | |
dc.contributor.author | Boumelha, J | |
dc.contributor.author | Kerr, DL | |
dc.contributor.author | Blakely, CM | |
dc.contributor.author | Manabe, T | |
dc.contributor.author | Martinez-Ruiz, C | |
dc.contributor.author | Bakker, B | |
dc.contributor.author | De Dios Palomino Villcas, J | |
dc.contributor.author | I Vokes, N | |
dc.contributor.author | Dietzen, M | |
dc.contributor.author | Angelova, M | |
dc.contributor.author | Gini, B | |
dc.contributor.author | Tamaki, W | |
dc.contributor.author | Allegakoen, P | |
dc.contributor.author | Wu, W | |
dc.contributor.author | Humpton, TJ | |
dc.contributor.author | Hill, W | |
dc.contributor.author | Tomaschko, M | |
dc.contributor.author | Lu, W-T | |
dc.contributor.author | Haderk, F | |
dc.contributor.author | Al Bakir, M | |
dc.contributor.author | Nagano, A | |
dc.contributor.author | Gimeno-Valiente, F | |
dc.contributor.author | de Carné Trécesson, S | |
dc.contributor.author | Vendramin, R | |
dc.contributor.author | Barbè, V | |
dc.contributor.author | Mugabo, M | |
dc.contributor.author | Weeden, CE | |
dc.contributor.author | Rowan, A | |
dc.contributor.author | McCoach, CE | |
dc.contributor.author | Almeida, B | |
dc.contributor.author | Green, M | |
dc.contributor.author | Gomez, C | |
dc.contributor.author | Nanjo, S | |
dc.contributor.author | Barbosa, D | |
dc.contributor.author | Moore, C | |
dc.contributor.author | Przewrocka, J | |
dc.contributor.author | Black, JRM | |
dc.contributor.author | Grönroos, E | |
dc.contributor.author | Suarez-Bonnet, A | |
dc.contributor.author | Priestnall, SL | |
dc.contributor.author | Zverev, C | |
dc.contributor.author | Lighterness, S | |
dc.contributor.author | Cormack, J | |
dc.contributor.author | Olivas, V | |
dc.contributor.author | Cech, L | |
dc.contributor.author | Andrews, T | |
dc.contributor.author | Rule, B | |
dc.contributor.author | Jiao, Y | |
dc.contributor.author | Zhang, X | |
dc.contributor.author | Ashford, P | |
dc.contributor.author | Durfee, C | |
dc.contributor.author | Venkatesan, S | |
dc.contributor.author | Temiz, NA | |
dc.contributor.author | Tan, L | |
dc.contributor.author | Larson, LK | |
dc.contributor.author | Argyris, PP | |
dc.contributor.author | Brown, WL | |
dc.contributor.author | Yu, EA | |
dc.contributor.author | Rotow, JK | |
dc.contributor.author | Guha, U | |
dc.contributor.author | Roper, N | |
dc.contributor.author | Yu, J | |
dc.contributor.author | Vogel, RI | |
dc.contributor.author | Thomas, NJ | |
dc.contributor.author | Marra, A | |
dc.contributor.author | Selenica, P | |
dc.contributor.author | Yu, H | |
dc.contributor.author | Bakhoum, SF | |
dc.contributor.author | Chew, SK | |
dc.contributor.author | Reis-Filho, JS | |
dc.contributor.author | Jamal-Hanjani, M | |
dc.contributor.author | Vousden, KH | |
dc.contributor.author | McGranahan, N | |
dc.contributor.author | Van Allen, EM | |
dc.contributor.author | Kanu, N | |
dc.contributor.author | Harris, RS | |
dc.contributor.author | Downward, J | |
dc.contributor.author | Bivona, TG | |
dc.contributor.author | Swanton, C | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2024-03-01T10:44:17Z | |
dc.date.available | 2024-03-01T10:44:17Z | |
dc.date.issued | 2024-01-01 | |
dc.identifier | 10.1038/s41588-023-01592-8 | |
dc.identifier.citation | Nature Genetics, 2024, 56 (1), pp. 60 - 73 | en_US |
dc.identifier.issn | 1061-4036 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6165 | |
dc.identifier.eissn | 1546-1718 | |
dc.identifier.eissn | 1546-1718 | |
dc.identifier.doi | 10.1038/s41588-023-01592-8 | |
dc.identifier.doi | 10.1038/s41588-023-01592-8 | |
dc.description.abstract | In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR mutant (EGFRmut) non-small-cell lung cancer (NSCLC) mouse models constrained tumorigenesis, while A3B expression in tumors treated with EGFR-targeted cancer therapy was associated with treatment resistance. Analyses of human NSCLC models treated with EGFR-targeted therapy showed upregulation of A3B and revealed therapy-induced activation of nuclear factor kappa B (NF-κB) as an inducer of A3B expression. Significantly reduced viability was observed with A3B deficiency, and A3B was required for the enrichment of APOBEC mutation signatures, in targeted therapy-treated human NSCLC preclinical models. Upregulation of A3B was confirmed in patients with NSCLC treated with EGFR-targeted therapy. This study uncovers the multifaceted roles of A3B in NSCLC and identifies A3B as a potential target for more durable responses to targeted cancer therapy. | |
dc.format | Print-Electronic | |
dc.format.extent | 60 - 73 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | NATURE PORTFOLIO | en_US |
dc.relation.ispartof | Nature Genetics | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Humans | |
dc.subject | Animals | |
dc.subject | Mice | |
dc.subject | Carcinoma, Non-Small-Cell Lung | |
dc.subject | Lung Neoplasms | |
dc.subject | Mutation | |
dc.subject | Up-Regulation | |
dc.subject | ErbB Receptors | |
dc.subject | Cytidine Deaminase | |
dc.subject | Minor Histocompatibility Antigens | |
dc.title | The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-10-25 | |
dc.date.updated | 2024-03-01T10:43:18Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1038/s41588-023-01592-8 | en_US |
rioxxterms.licenseref.startdate | 2024-01-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/38049664 | |
pubs.issue | 1 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Biology/Lung Cancer Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Closed research teams/Lung Cancer Group | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1038/s41588-023-01592-8 | |
pubs.volume | 56 | |
icr.researchteam | Lung Cancer Group | en_US |
dc.contributor.icrauthor | Downward, Julian David Harry | |
icr.provenance | Deposited by Mr Arek Surman on 2024-03-01. Deposit type is initial. No. of files: 1. Files: The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.pdf | |